Nephrologists Lag Behind in Lupus Nephritis Biologics and CNI Use

Renal & Urology News highlights new Spherix Global Insights research showing that rheumatologists are more likely than nephrologists to incorporate biologic- and calcineurin inhibitor (CNI)-containing combination regimens into lupus nephritis treatment.

Presented at ASN Kidney Week 2026, the analysis examined 1,074 patient charts from 111 rheumatologists and 89 nephrologists. Biologic- or CNI-containing combinations with mycophenolate mofetil or cyclophosphamide were used in 50% of rheumatology-managed patients compared with 36% of nephrology-managed patients. The difference was driven primarily by biologic use, which appeared in 33% of rheumatology charts compared with 21% of nephrology charts.

The findings also point to differences in how specialists select advanced therapies. CNI-containing regimens were more frequently used in patients with greater proteinuria and membranous disease, while biologics emerged as the more common add-on strategy overall. Despite higher proteinuria at treatment initiation among patients receiving voclosporin, most-recent proteinuria levels were similar between voclosporin- and belimumab-treated patients.

Key Takeaways

Rheumatologists Are Further Ahead in Combination Therapy Adoption

Half of rheumatology-managed patients received biologic- or CNI-containing combination therapy compared with just over one-third of nephrology-managed patients, highlighting a meaningful specialty gap in the uptake of guideline-supported treatment approaches.

Biologic Use Drives the Specialty Difference

Biologic-containing regimens were used substantially more often by rheumatologists, while CNI-only combinations were slightly more common among nephrologists.

Patient Phenotype Influences Treatment Selection

CNI use was highest among patients with membranous lupus nephritis and greater proteinuria, suggesting that physicians are differentiating between biologics and CNIs based on renal presentation and disease characteristics.

Featured Insight

As lupus nephritis treatment moves toward earlier use of multi-agent therapy, real-world adoption remains uneven across specialties. Understanding how rheumatologists and nephrologists differ in treatment selection may be increasingly important as manufacturers evaluate positioning, physician education, and opportunities to support broader uptake of advanced therapies.

Read the Full Article

Read the full coverage from Renal & Urology News:

Lupus Nephritis Biologics/CNI Use: Nephrologists Lag Behind

Original source: Renal & Urology News

Sign up for alerts, market insights and exclusive content in your inbox.